Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema by Figueras-Roca, Marc et al.
Retina
Anatomic Response to Intravitreal Dexamethasone
Implant and Baseline Aqueous Humor Cytokine Levels in
Diabetic Macular Edema
Marc Figueras-Roca,1,2 Anna Sala-Puigdollers,1,2 Javier Zarranz-Ventura,1,2 Carmen Alba-Linero,1
Socorro Alforja,1,2 Cristina Esquinas,3 Blanca Molins,2 and Alfredo Ada´n1,2
1Institut Cl´ınic d’Oftalmologia (ICOF), Hospital Cl´ınic, Barcelona, Spain
2August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
3Respiratory Department, Hospital Universitari Vall d’Hebro´n, Barcelona, Spain
Correspondence: Marc Figueras-Ro-
ca, Institut Clinic d’Oftalmologia
(ICOF), Hospital Cl´ınic, Sabino de
Arana 1, Barcelona 08028, Spain;
mafiguer@clinic.cat.
Submitted: November 16, 2018
Accepted: March 3, 2019
Citation: Figueras-Roca M, Sala-Puig-
dollers A, Zarranz-Ventura J, et al.
Anatomic response to intravitreal
dexamethasone implant and baseline
aqueous humor cytokine levels in
diabetic macular edema. Invest Oph-
thalmol Vis Sci. 2019;60:1336–1343.
https://doi.org/10.1167/iovs.18-26215
PURPOSE. To determine whether baseline cytokine aqueous humor (AH) levels are associated
with diabetic macular edema (DME) anatomic response to dexamethasone intravitreal implant
(DEX) injection.
METHODS. This was a prospective cohort study of DME cases receiving DEX treatment. Seventy
patients were recruited with center-involving DME with spectral-domain (SD) optical
coherence tomography (OCT) detection of central macular thickness (CMT) ‡300 lm on
macular cube 518 3 128-lm scan protocol (Cirrus SD-OCT). DEX injection and anterior
chamber tap to obtain an AH sample were performed at the same time. Multiplex
immunoassay was carried out for interleukin (IL)-1b, IL-3, IL-6, IL-8, IL-10; monocyte
chemoattractant protein (MCP)-1; interferon gamma-induced protein (IP)-10; tumor necrosis
factor (TNF)-a; and vascular endothelial growth factor (VEGF). A follow-up visit and OCT
exam were undertaken 6 to 8 weeks afterward. The association between AH cytokine
baseline levels and change in CMT and macular volume (MV) was defined as main outcome
measure.
RESULTS. Multivariate linear regression analysis showed a higher decrease in MV to be
associated (Rs of 0.512) with four baseline items: higher MCP-1 (b ¼ 0.4; P ¼ 0.028), higher
CMT (b ¼ 0.003; P ¼ 0.024), decreased visual acuity (b ¼ 0.7; P ¼ 0.040), and a diffuse
retinal thickening (DRT) OCT pattern (b ¼ 1.3; P < 0.001). Logistic regression found DRT
also to be associated with higher odds of a good MV response (odds ratio, 31.96; 95%
confidence interval [CI] 7.11–143.72; P < 0.001).
CONCLUSIONS. Even though visual acuity response and anatomic effect are not always
correlated in DME, we found that baseline elevated MCP-1 AH levels and DRT pattern were
biomarkers that predicted a future favorable anatomic response to DEX.
Keywords: cytokine, diabetic macular edema, intravitreal dexamethasone
Diabetic macular edema (DME) is the most common cause ofvision loss in diabetes mellitus (DM) patients with diabetic
retinopathy (DR) in a developed society.1–3 DME formation is
driven by capillary leakage and fluid accumulation within retinal
tissue causing thickening, macular malfunction, and visual
impairment. Cellular events such as leukostasis, abnormal
leukocyte adherence, and increased vascular permeability take
place under the control of intracellular mediators such as
cytokines, chemokines, and growth factors.4,5 Thus, DME
patients have been shown to have increased aqueous humor
(AH) levels of molecules such as intercellular adhesion molecule-
1 (ICAM-1); interleukin (IL)-1b, IL-6, IL-8; interferon gamma-
induced protein-10 (IP-10); monocyte chemoattractant protein-1
(MCP-1); and vascular endothelial growth factor (VEGF), with
comparatively lower levels of IL-10 and IL-12 than in diabetic
patients without DME.6,7 In addition, recent studies have
reported that some agents, such as ICAM-1, IL-8, and MCP-1,
may even be objectively correlated to DME severity based on
optical coherence tomography (OCT) measurements.6–8
Current DME management involves intravitreal injection of
different drugs as first-line therapy in sight-threatening disease.
Anti-VEGF agents first and steroids, which are commonly used
as a second-line approach, are both nowadays licensed for DME
treatment. The mechanism of action of anti-VEGF drugs directly
involves intraocular VEGF blockade with subsequent inhibition
of angiogenesis and also inflammation.4,9 On the other hand,
the effect of steroids is based on the inhibition of phospholi-
pase A2, thus blocking an upstream component of the
molecular pathway of inflammation and therefore affecting
the expression of additional agents such as tumor necrosis
factor alpha (TNF-a), ICAM-1, and its resulting inflammatory
mediators.10 Even though anti-VEGF drugs (bevacizumab,
ranibizumab, and aflibercept) show some slight differences in
blocking VEGF isoforms, their efficacy in DME is similar in
patients with relatively good vision.11–13 However, the DME
clinical response to steroids, such as dexamethasone 0.7-mg
intravitreal implant (DEX) (Ozurdex; Allergan, Inc., Irvine, CA,
USA), differs significantly from that for anti-VEGF agents, not
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only because of its mechanism of action but also by its
prolonged activity due to its sustained intraocular re-
lease.10,14–16 Moreover, DEX has indeed proven to be effective,
in terms of both visual acuity and macular anatomy, in DME
cases that did not respond to prior anti-VEGF treatment, thus
enforcing the importance of its different mechanism of
action.17,18
Given such differences between DME intravitreal therapies,
several studies have investigated how these drugs change the
intraocular milieu of inflammatory and pro-permeability
mediators. Previous reports have claimed that intravitreal
bevacizumab (IVB) decreases AH VEGF levels with no effect
on IL-6, IL-8, IP-10, and MCP-1.14,19 Moreover, intravitreal
ranibizumab (IVR) (Lucentis; Genentech, Inc., San Francisco,
CA, USA) has also been shown not to affect AH levels of
different molecules such as IL-1Ra, IL-5, IL-6, IL-8, IP-10, MCP-1,
and TNF-a.20 On the other hand, steroid agents have proven to
have an impact on the distribution of several mediators. For
example, intravitreal triamcinolone acetonide has been report-
ed to differentially decrease intraocular IL-6, IP-10, MCP-1, and
platelet-derived growth factor (PDGF)-AA when compared to
IVB in DME.19 Similarly, significant associations have also been
described between the DEX effect on DME thickening and
several AH levels of inflammatory mediators such as insulin-like
growth factor binding protein (IGFBP)-1, IGFBP-3, prolactin,
matrix metalloproteinase (MMP)-9, endocrine-gland VEGF (EG-
VEGF), endostatin, angiopoietin-2, persephin, MIP-1, thrombo-
spondin (THSP)-2, hepatocyte growth factor (HGF), IL-8, and
C-X-C motif ligand (CXCL)-16.21 Finally, recent studies have
even described an association between baseline levels of some
AH agents such as ICAM-1 and eotaxin-1 with DME response to
IVR objectively measured by OCT.22
In summary, the main objective of this study was to
determine the relationship between baseline AH levels of
several cytokines and growth factors and DME anatomic
response to DEX, quantitatively measured by OCT. Moreover,
additional clinically relevant baseline characteristics, including
treatment status, DME OCT patterns, and other ocular
comorbidities were investigated.
METHODS
Study and Participants
This was an observational, prospective, 2-month follow-up
study. Participants were adults with type 1 or 2 diabetes and
DR with center-involving DME as defined by the international
scale,23,24 with Early Treatment Diabetic Retinopathy Study
(ETDRS)–defined central macular thickness (CMT) ‡300 lm
on spectral-domain (SD) OCT (Cirrus SD OCT; Carl Zeiss
Meditec, Inc., Dublin, CA, USA). Selection for DEX treatment
was based on common clinical practice standards: on one
hand, previously anti-VEGF–treated patients with poor re-
sponse and, on the other hand, treatment–naive DME cases
that could not cope with monthly treatment regimens.
Exclusion criteria included proliferative DR, prior intraocular
surgery of any kind beyond uncomplicated cataract removal,
intravitreal injection of any anti-VEGF agent within 3 months,
and any steroid drug injection within 6 months prior to the
inclusion date. Whenever DME was bilaterally present, the eye
with a higher CMT determined by SD-OCT was selected as the
study eye. The study took place from January 2015 to February
2018 and was approved by the local Insitutional Review Board
(Ethics and Clinical Investigation Commitee, Hospital Cl´ınic of
Barcelona) and carried out according to the Declaration of
Helsinki. All participants provided written informed consent to
join the study.
Study Protocol
Each patient received DEX injection with undiluted AH fluid
collection (0.1 mL) at the same time by an anterior chamber tap.
All intravitreal injections were performed by a retina specialist
under topical anesthesia and sterile conditions after povidone
iodine 5% was instilled on THE conjuntival fornix. Taps were
performed using a 30-gauge needle with a tuberculin syringe
through a limbal paracentesis. DEX implant was then injected 4
mm from the limbus on the superotemporal quadrant and the
optic nerve head perfusion checked. Topical ofloxacin 0.3% three
times a day was administered on the same day and 3 days
afterward. All AH specimens were immediately transferred to a
sterile tube and stored at708C until assayed.
Nine different immune mediators were measured in the AH
samples: proinflammatory agents (IL-1b, IL-3, IL-6, IL-8, MCP-1,
IP-10), type 1 cytokines (TNF-a), type 2 cytokines (IL-10), and
growth factors (VEGF). These molecules were selected based
on previously published studies regarding AH levels of
cytokines, chemokines, and growth factors in DME.6,7 The
Luminex platform (Millipore MilliPlex Human Cytokine/Che-
mokine kit; Merck Millipore, Inc., Burlington, MA, USA) was
used to measure such molecule levels in AH samples using an
assay plate layout consisting of seven standards in duplicate
(3.2–2000 pg/mL), one blank well (for background fluores-
cence subtraction), two internal quality control samples in
duplicate, and 25 lL duplicates of each sample. The MilliPlex
method was performed as recommended by the manufacturer.
Zero values were statistically handled as a third of the provided
detection limit. Uncertainty regarding the reliability of three
cytokine measurements (IL-1b, IL-3, and IL-10) was found due
to their determinations generally staying at the lower
sensitivity limit for the immunoassay. These molecules were
finally excluded from the analysis.
Every participant underwent a complete ocular examina-
tion to assess DME severity prior to treatment and in the first
follow-up visit to be scheduled 6 to 8 weeks after AH sampling
and DEX injection. It included a comprehensive ophthalmic
assessment, concomitant diseases and treatments, best-correct-
ed visual acuity (BCVA) by Snellen chart recording (and
conversion to logMAR for statistical analysis), IOP measure-
ment, slit-lamp and fundus examination under pupil dilation,
DR grading per the international-based scale,23 and SD-OCT
examination using a standard macular cube 518 3 128-lm
protocol. The analysis of OCT images included the determina-
tion of quantitative parameters such as CMT and MV
determined with the built-in manufacturer software, as well
as qualitative features such as DME patterns classified as diffuse
retinal thickening (DRT), cystoid macular edema, serous retinal
detachment, epirretinal membrane, and hyperreflective retinal
spots as defined by previously published studies.25–28
Study Outcomes
Changes in CMT and MV after treatment were set as primary
study outcomes. In addition, all patients were categorized into
responders and nonresponders on both CMT and MV
characteristics in a similar manner to that reported in already
published investigations. A CMT responder was defined as a
patient with 50% or greater reduction in excess CMT (>300
lm) from baseline to 6 to 8 weeks follow-up.22 An MV
responder was defined in the same way as a patient with a 10%
or greater reduction in MV.22
Statistical Analysis
Absolute frequencies and percentages were used to describe
categorical variables. The description of quantitative variables
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was performed using mean, standard deviation (SD), median,
and interquartile interval. The Kolmogorov-Smirnov test was
used to assess the normality of distributions. Changes in
clinical features between baseline and 6- to 8-week visits were
analyzed using a paired t-test. Linear relationships between
changes in CMT and MV during follow-up and cytokine levels at
baseline were carried out by Spearman correlation coefficient
analysis. Cytokine concentrations were log-transformed in
order to decrease variability for the two multivariate models.
Back stepwise linear regression models were developed
including changes in CMT and MV during follow-up as
dependent variables. Variables with a significance <0.1 in the
univariate analysis were included as independent factors.
Adjusted Rs and regression for each model was also provided.
Similarly, two back stepwise logistic regression models were
carried out including CMT and MV responder as dependent
variables. The Hosmer-Lemeshow goodness-of-fit test was
performed to assess the overall fit of the model. For all the
tests P values <0.05 were considered statistically significant.
The statistical package R Studio 2.5 (www.R-project.org) was
used for the statistical analyses.29
RESULTS
Seventy cases from 70 participants were included in the study
and analysis. Baseline characteristics are summarized in Table
1. DME evaluation was performed 6 to 8 weeks after DEX
injection at a mean (SD) of 49 (19) days. DME ophthalmologic
assessment changes with DEX, including BCVA, IOP, CMT, and
MV, are shown in Table 2. Mean logMAR (SD) BCVA improved
from 0.61 (0.41) to 0.55 (0.42) whereas CMT and MV both
decreased from 453 lm (116) and 12.13 mm3 (2.10) to 324 lm
(80) and 10.76 mm3 (1.41), respectively. There was a rise in
mean IOP (SD) from baseline 16.91 mm Hg (3.03) to 19 mm Hg
(4.65) at follow-up, which was also statistically significant.
Statistically signficant correlations were found between MV
change and baseline AH levels of IL-6 (r¼0.36; P¼ 0.002), IL-
8 (r¼0.34; P¼ 0.004), IP-10 (r¼0.28; P¼ 0.021), and MCP-
1 (r¼0.31; P¼ 0.009), with no correlations being observerd
between any AH mediator and CMT change (Table 3; Fig.). The
multivariate linear regression model (Table 4) showed that
higher baseline MV (b¼24; P < 0.001) and presence of prior
panretinal photocoagulation (PRP) (b ¼ 105.7; P < 0.001)
were associated with a higher decrease in CMT (Rs of 0.309).
On the other hand, a higher decrease in MV was associated (Rs
of 0.512) with higher baseline MCP-1 (b ¼0.4; P ¼ 0.028),
higher CMT prior to treatment (b ¼ 0.003; P ¼ 0.024),
decreased baseline BCVA per increased logMAR determination
(b ¼0.7; P ¼ 0.040), and presence of DRT (b ¼1.3; P <
0.001). No other baseline AH mediators or other variables were
associated with CMT or MV change.
Regarding DME response to DEX as a categorized variable,
59 of 70 participants (84.3%) were found to be CMT
responders based on the definition previously described.
Thirty-three of 70 were defined as responders according to
MV change. Backwise logistic regression models showed that
the existence of a baseline DRT pattern of DME (odds ratio
[OR], 31.96; 95% CI 7.11–143.72; P < 0.001) and a decreased
BCVA at baseline per increased logMAR determination (OR,
9.24; 95% CI 1.06–80.58; P ¼ 0.044) were independently
related to MV response (Hosmer-Lemeshow P ¼ 0.42). No
baseline variable or AH mediator was found to be associated
with being defined as a responder by CMT change.
DISCUSSION
Assessing macular edema response to intravitreal treatment is
one of the most challenging topics nowadays in retinal disease.
TABLE 1. Baseline Characteristic Features
Characteristics Value
Demographic, n ¼ 70
Age, mean (SD) [range], years 71 (9.1) [51–89]
Sex, no. (%)
Male 37 (52.9)
Female 33 (47.1)
Laterality, no. (%)
Right 34 (48.6)
Left 36 (51.4)
Lens status, no. (%)
Phakic 39 (55.7)
Pseudophakic 31 (44.3)
Intraocular pressure, mean (SD) mm Hg 16.9 (3)
Best-corrected visual acuity
Snellen, mean (range) 20/63 (20/25–20/800)
LogMAR, mean (SD) [range] 0.6 (0.4) [0.1–2]
OCT features
Central macular thickness, mean (SD)
[range], lm
453.2 (116.1) [302–924]
Macular volume, mean (SD) [range], mm3 12.1 (2.1) [7–17.2]
Grading of diabetic retinopathy, no. (%)
Mild 20 (28.6)
Moderate 37 (52.9)
Severe 13 (18.6)
Duration of diabetes, mean (SD)
[range], years
13.5 (8.4) [1–40]
HbA1c, mean (SD) [range], %, n ¼ 44 7.7 (1.5) [5.5–12.3]
Prior DME treatment, no. (%)
Yes 44 (62.9)
No 26 (37.1)
Previous DME treatment, sole or combination, no. (%), n ¼ 44
Intravitreal anti-VEGF 25 (56.8)
Intravitreal DEX implant 22 (50)
Intravitreal TCA 6 (13.6)
Macular laser 11 (25)
Abbreviations: HbA1c, hemoglobin A1c; TCA, triamcinolone aceto-
nide.
TABLE 2. Changes in Clinical Features Between Baseline and 6- to 8-Weeks Visit
Study Characteristic Baseline 6–8 Weeks Change P Value*
Best-corrected visual acuity
LogMAR, mean (SD) 0.61 (0.41) 0.55 (0.42) 0.07 (0.17) 0.001
IOP, mean (SD), mm Hg 16.91 (3.03) 19 (4.65) 2.07 (4.67) <0.001
OCT features
CMT, mean (SD), lm 453 (116) 324 (80) 129 (116) <0.001
MV, mean (SD), mm3 12.13 (2.10) 10.76 (1.41) 1.37 (1.28) <0.001
* Statistically significant at P < 0.05.
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TABLE 3. Baseline AH Mediator Levels and Correlation to DME Anatomic Response
Intraocular
Mediator
AH Level,
Median (IQI), pg/mL
Correlation to
CMT Change* P Value†
Correlation to
MV Change* P Value†
IL-6 6.3 (1; 32.4) 0.22 0.071 0.36 0.002
IL-8 14.1 (6.7; 30.4) 0.23 0.060 0.34 0.004
IP-10 240.5 (163.6; 597.7) 0.17 0.156 0.28 0.021
MCP-1 3212.9 (2097.2; 6933.1) 0.14 0.261 0.31 0.009
TNF-a 0.3 (0.2; 2.2) 0.08 0.511 0.02 0.855
VEGF 73.1 (8.8; 190.4) 0.15 0.249 0.05 0.724
Abbreviation: IQI, interquartile interval.
* Spearman correlation coefficient.
† Statistically significant at P < 0.05.
FIGURE. Series of scatter plots representing correlations between cytokine (IL-6, IL-8, IP-10, MCP-1, TNF-a, and VEGF) aqueous humor levels (pg/
mL) and OCT-based macular volume (mm3) change (DMV) due to intravitreal dexamethasone implant injection for DME. Showing drawn line as
correlation. Note that y-axis set on logarithmic scale.
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Even though BCVA remains the main outcome in most studies
and keeps a direct relation to the patient perception of visual
health, its clinical application is limited by myriad confounding
factors such as macular ischemia and chronic tissue damage,
frequently associated with advanced stages of DR and long-
standing DME. On the other hand, CMT is still considered the
objective quantitative gold-standard indicator of macular
edema severity. However, it can have important variability
errors when measuring retinal thickness in the ETDRS 1-mm-
diameter subfield.29 Moreover, due to its reduced area, CMT
does not always correctly reflect generalized macular thicken-
ing if the central subfield is spared. Nonetheless, MV has
recently emerged as a better indicator of macular edema
severity and its response to treatment overcoming some
traditionally important existing biases in both BCVA and
CMT.6,8,22
The key point of the present study is therefore to present
results of DEX treatment for DME based on MV in addition to
CMT, similarly to recently published studies on the effect of
anti-VEGF drugs in DME.22 For instance, some published
reports on DEX and DME have already shown CMT changes to
be correlated to several AH cytokines, but again, important
biases related to the use of CMT as a surrogate marker of
treatment response limit the extent of their conclusions.21 Our
study found MV change with DEX to be correlated to several
AH mediators such as IL-6, IL-8, IP-10, and MCP-1, with no
association to CMT change (Table 3; Fig.). When multivariate
linear regression models were applied, MV change was found
to keep the association to MCP-1 AH levels as well as a DRT
pattern of DME cases on OCT, all together with baseline CMT
and BCVA. Interestingly, this model performed a notable
predictability of MV change (Rs ¼ 0.512), contrary to that of
CMT change (Rs ¼ 0.309) that was mainly related to baseline
MV and existing PRP (Table 4). It remains unclear whether
prior PRP itself could influence CMT response but not MV
response, given the existing CMT interpretation biases. Finally,
when response to treatment was categorized in a dichotomized
manner, no association was observed regarding CMT; never-
theless, MV changes kept the OCT diffuse pattern of DME and
baseline BCVA as predictors.
As a whole, our results suggest that two items, MCP-1 and
DRT, bear an important predictive value of overall macular
edema response to DEX therapy and could therefore be
proposed as effective biomarkers prior to treatment. On the
other hand, the baseline CMT role regarding MV change has to
be carefully considered, as both items are extracted from the
same OCT images and therefore biases could exist. In fact, MV
has also been found to influence CMT. In a similar way, the
association between low BCVA and increased MV response is
consistent with everyday clinical practice but also has to be
carefully handled, taking into consideration all confounders
affecting visual function in DME and DR.
MCP-1, also referred to as chemokine (C-C motif) ligand 2
(CCL2), is a chemokine inducing monocyte and macrophage
infiltration to tissues with angiogenic properties.30 In vivo
models of blood–retinal barrier and DR have even experimen-
tally shown MCP-1 to be directly involved in retinal microglia
activation, thus highlighting its crucial role in this situation.31
Although MCP-1 is widely considered to be associated with
DME,6,7 there is a paucity of information regarding its AH level
response to intravitreal steroid injection in such a setting or its
relation to retinal thickening changes with treatment.19,21
Interestingly, however, some published reports found MCP-1
AH level to decrease with DEX injection for retinal vein
occlusion–derived macular edema.32 By means of the current
results, we have proven MCP-1 to be directly related to MV
change in DME under DEX treatment. This finding is consistent
with the general understanding of the steroid effect on DME
and, moreover, highlights this molecule as a crucial role-playing
agent in DME.
Contrary to MCP-1 behavior, VEGF levels have not been
found to have any correlation to DEX effect on DME by OCT
measurements. Previous reports on this topic also failed to find
an association between DEX and VEGF ocular isoforms,21,32
despite existing publications on other steroid agents such as
triamcinolone acetonide.19 Interestingly, Hillier et al.22 recently
reported VEGF AH levels to be inversely correlated to DME MV
response to IVR. This paradoxical point, which is reinforced by
our findings, suggests the existence of many more acting
mediators in DME besides VEGF.
On the other hand, DME presenting with a diffuse
thickening of the retina has also been found to be predictive
of MV response to DEX. OCT-based patterns of DME have been
a well-studied issue, especially regarding their relation to AH
mediators and response to treatment. For instance, serous
retinal detachment has been the most widely reported pattern
to be associated with intraocular inflammation by means of
increased AH mediator levels, such as IL-6,26,27,33 but also
showing the predictive value of better BCVA response to DEX
treatment.34 However, diffuse macular thickening is also
associated with increased AH levels of several cytokines6,26
and has even been related to increased peripheral blood serum
levels of IL-6.35 With such a background, our finding of DRT as
an independent predictive variable of MV change is important,
as this is an OCT-derived feature that can be easily identified in
a routine clinical practice setting and has been proven to
increase the odds of an MV response defined as ‡10%
reduction in such parameter.
Limitations
The present study has some limitations. First, although AH is
the most used intraocular specimen nowadays to study retinal
diseases,5,36,37 the analysis of the vitreous fluid should be
considered the ideal sample in such cases.38,39 However, unless
vitreoretinal surgery is mandatory due to DR complications,
obtaining vitreous samples for research purposes in DME is
nowadays not practical nor ethically fully feasible. Therefore,
AH is considered the most adequate biological sample for
looking for intraocular biomarkers in DME, as claimed by
several recent investigations.6,21,22 Second, lacking an AH
sample obtained in the immediate follow-up could have limited
the extent of our conclusions since it could have determined
how the searched mediators changed with DEX end of action
and DME eventual relapse. This point may set up subsequent
investigations to come to further validate our findings. Third,
this study evaluated a large number of cytokines and thus
statistical errors related to multiple testing could have occured,
even if appropiate controlling measures and multivariate
analysis were undertaken accordingly. Finally, our series lacks
an angiographic macular evaluation with conventional fundus
fluorescein angiography, as seen in similar previous reports,22
which could limit the outcomes reported due to undetected
macular ischemia, especially regarding BCVA outcomes.
CONCLUSIONS
In summary, our data enforce the general understanding of
DME as a complex entity with myriad involved correlated
agents. Through complex analysis, some of these items can be
considered biomarkers of disease severity and, in this case,
even of DME response to DEX treatment. Apart from the
suggested limitations of this work, these findings may
contribute to understanding the effect of steroid drugs in the
intraocular media of DME cases and could set interesting
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starting points for future investigations. We have highlighted
the role of MCP-1 as a crucial molecule in the DME process,
which may be able to predict MV change with DEX treatment
and therefore be considered in individualized treatment
algorithms based on baseline analysis of biologic samples.
Moreover, an OCT-based DME feature, DRT, has shown
potential value in predicting treatment response. The data
presented support a possible future reality in DME manage-
ment in which imaging and biologic features may be used in a
form of personalized medicine to predict response to
treatment.
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